In their living guidelines for the treatment of hospitalized patients with coronavirus disease
2019 (COVID-19), Bartoletti and colleagues make a conditional recommendation to use …

Background♦ Remdesivir (RDV) reduced time to recovery and improved clinical outcomes
for COVID-19 patients in several randomized controlled trials1, 2; with additional evidence …

We thank Beccacece et al. for their letter to the editor notifying that a study that we included
in our recent meta-analysis has since been retracted. We believe that it is paramount to …

Background The antiviral efficacy of remdesivir against SARS-CoV-2 is still controversial.
We aimed to evaluate the clinical efficacy of remdesivir plus standard of care compared with …

We read with interest the systematic review and meta-analysis by Lee et al.[1] concerning
the use of remdesivir for the treatment of patients with coronavirus disease 2019. The …

room air (moderate‑to‑severe cases) if it is administered within 7–10 days of illness.
Remdesivir led to a shorter median time from randomization to recovery (10 days, vs. 15 …

Remdesivir is approved for the treatment of hospitalized coronavirus disease 2019 (COVID-
19) patients. 1 Up to 5%–10% of discharged COVID-19 patients require readmission, most …

CI confidence interval aCurrent evidence supporting the use of remdesivir in patients with
mild or moderate COVID-19 (no oxygen therapy required)[1] is insufficient bOff-label-use …

In their Letter to the Editor “Remdesivir for COVID-19: Why Not Dose Higher?” Yan and
Muller assert that the clinical efficacy of remdesivir at its currently approved dose (200 mg …

Summary Background The Solidarity trial among COVID-19 inpatients has previously
reported interim mortality analyses for four repurposed antiviral drugs. Lopinavir …